Generalizability of findings from a clinical sample to a community-based sample: A comparison of ADNI and ARIC
- PMID: 33527720
- PMCID: PMC8359773
- DOI: 10.1002/alz.12293
Generalizability of findings from a clinical sample to a community-based sample: A comparison of ADNI and ARIC
Abstract
Introduction: Clinic-based study samples, including the Alzheimer's Disease Neuroimaging Initiative (ADNI), offer rich data, but findings may not generalize to community-based settings. We compared associations in ADNI to those in the Atherosclerosis Risk in Communities (ARIC) study to assess generalizability across the two settings.
Methods: We estimated cohort-specific associations among risk factors, cognitive test scores, and neuroimaging outcomes to identify and quantify the extent of significant and substantively meaningful differences in associations between cohorts. We explored whether using more homogenous samples improved comparability in effect estimates.
Results: The proportion of associations that differed significantly between cohorts ranged from 27% to 34% across sample subsets. Many differences were substantively meaningful (e.g., odds ratios [OR] for apolipoprotein E ε4 on amyloid positivity in ARIC: OR = 2.8, in ADNI: OR = 8.6).
Discussion: A higher proportion of associations differed significantly and substantively than would be expected by chance. Findings in clinical samples should be confirmed in more representative samples.
Keywords: Alzheimer's Disease Neuroimaging Initiative; Alzheimer's disease; Atherosclerosis Risk in Communities; dementia; generalizability.
© 2021 the Alzheimer's Association.
Conflict of interest statement
Declaration of interest
KZG, EEB, JW, MLM, EAS, MEG, MMG, and MCP have nothing to declare
RFG is an associate editor for the journal Neurology
DFW has related grants from NIH and have previously received contracts through John Hopkins University from Roche and Lundbeck for dementia imaging in 2019.
TM, DJC have related grants from NIH
Figures
Similar articles
-
Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.JAMA Neurol. 2020 Apr 1;77(4):470-479. doi: 10.1001/jamaneurol.2019.4421. JAMA Neurol. 2020. PMID: 31860000 Free PMC article.
-
ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels.JAMA Neurol. 2023 Dec 1;80(12):1295-1306. doi: 10.1001/jamaneurol.2023.4038. JAMA Neurol. 2023. PMID: 37930695
-
Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts.Brain. 2022 Nov 21;145(11):4065-4079. doi: 10.1093/brain/awac213. Brain. 2022. PMID: 35856240 Free PMC article.
-
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.Alzheimers Dement. 2019 Jan;15(1):106-152. doi: 10.1016/j.jalz.2018.08.005. Epub 2018 Oct 13. Alzheimers Dement. 2019. PMID: 30321505 Review.
-
Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative.Alzheimers Dement. 2015 Jul;11(7):730-3. doi: 10.1016/j.jalz.2015.05.007. Alzheimers Dement. 2015. PMID: 26194308 Free PMC article. Review.
Cited by
-
Impact of white matter hyperintensities on structural connectivity and cognition in cognitively intact ADNI participants.Neurobiol Aging. 2024 Mar;135:79-90. doi: 10.1016/j.neurobiolaging.2023.10.012. Epub 2023 Dec 12. Neurobiol Aging. 2024. PMID: 38262221
-
The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022.Alzheimers Dement. 2024 Jan;20(1):652-694. doi: 10.1002/alz.13449. Epub 2023 Sep 12. Alzheimers Dement. 2024. PMID: 37698424 Review.
-
The Mediating Roles of Neurobiomarkers in the Relationship Between Education and Late-Life Cognition.J Alzheimers Dis. 2023;95(4):1405-1416. doi: 10.3233/JAD-230244. J Alzheimers Dis. 2023. PMID: 37694365 Free PMC article.
-
Emerging diagnostics and therapeutics for Alzheimer disease.Nat Med. 2023 Sep;29(9):2187-2199. doi: 10.1038/s41591-023-02505-2. Epub 2023 Sep 4. Nat Med. 2023. PMID: 37667136 Review.
-
Biomarkers of Alzheimer's disease in Black and/or African American Alzheimer's Disease Neuroimaging Initiative (ADNI) participants.Neurobiol Aging. 2023 Nov;131:144-152. doi: 10.1016/j.neurobiolaging.2023.07.021. Epub 2023 Jul 20. Neurobiol Aging. 2023. PMID: 37639768
References
-
- Alzheimer’s Disease Neuroimaging Initiative. Study Design. Alzheimer’s Disease Neuroimaging Initiative. http://adni.loni.usc.edu/study-design/. Published 2017. Accessed September 24, 2019.
Publication types
MeSH terms
Substances
Grants and funding
- U01 HL096917/HL/NHLBI NIH HHS/United States
- HHSN268201700004C/HB/NHLBI NIH HHS/United States
- U01 AG024904/AG/NIA NIH HHS/United States
- U01 HL096902/HL/NHLBI NIH HHS/United States
- R01 AG040282/AG/NIA NIH HHS/United States
- HHSN268201700002C/HL/NHLBI NIH HHS/United States
- HHSN268201700001I/HL/NHLBI NIH HHS/United States
- HHSN268201700004I/HL/NHLBI NIH HHS/United States
- U01 HL096814/HL/NHLBI NIH HHS/United States
- R01 HL070825/HL/NHLBI NIH HHS/United States
- U01 HL096899/HL/NHLBI NIH HHS/United States
- HHSN268201700003I/HL/NHLBI NIH HHS/United States
- R01 AG057869/AG/NIA NIH HHS/United States
- U01 HL096812/HL/NHLBI NIH HHS/United States
- HHSN268201700005C/HL/NHLBI NIH HHS/United States
- HHSN268201700001C/HL/NHLBI NIH HHS/United States
- HHSN268201700003C/HL/NHLBI NIH HHS/United States
- HHSN268201700002I/HL/NHLBI NIH HHS/United States
- HHSN268201700005I/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
